Rosuvastatin
ANCA-associated Primary Necrotizing Vasculitides
Assistance Publique - Hôpitaux de ParisSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the ANCA-associated Primary Necrotizing Vasculitides cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bcma-Cd19 Ccar T Cells Peking University People's Hospital | Phase 2 | CCC |
Ucar T-Cell The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | CCC |
qt-219cx The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
Rosuvastatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →